 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes THIOTHIXENE increase or decrease the risk of myocardial [0m
[34minfarction?[0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does THIOTHIXENE increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes THIOTHIXENE increase or decrease the risk of myocardial [0m
[32minfarction?[0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes THIOTHIXENE increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does THIOTHIXENE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"THIOTHIXENE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: THIOTHIXENE: adverse_reactions: ADVERSE REACTIONS NOTE : Not all of the following adverse reactions have been reported with thiothixene. However, since thiothixene has certain chemical and [0m
[31mpharmacologic similarities to the phenothiazines, all of the known side effects and toxicity associated with phenothiazine therapy should be borne in mind when thiothixene is used. Cardiovascular [0m
[31mEffects Tachycardia, hypotension, lightheadedness, and syncope. In the event hypotension occurs, epinephrine should not be used as a pressor agent since a paradoxical further lowering of blood [0m
[31mpressure may result. Nonspecific EKG changes have been observed in some patients receiving thiothixene. These changes are usually reversible and frequently disappear on continued thiothixene therapy. [0m
[31mThe incidence of these changes is lower than that observed with some phenothiazines. The clinical significance of these changes is not known. THIOTHIXENE: adverse_reactions: CNS Effects Drowsiness, [0m
[31musually mild, may occur although it usually subsides with continuation of thiothixene therapy. The incidence of sedation appears similar to that of the piperazine group of phenothiazines but less than[0m
[31mthat of certain aliphatic phenothiazines. Restlessness, agitation and insomnia have been noted with thiothixene. Seizures and paradoxical exacerbation of psychotic symptoms have occurred with [0m
[31mthiothixene infrequently. Hyperreflexia has been reported in infants delivered from mothers having received structurally related drugs. In addition, phenothiazine derivatives have been associated with[0m
[31mcerebral edema and cerebrospinal fluid abnormalities. Extrapyramidal Symptoms Extrapyramidal symptoms, such as pseudoparkinsonism, akathisia and dystonia have been reported [0m[1;31m([0m[31msee Dystonia, Class effect[0m
[1;31m)[0m[31m. Management of these extra-pyramidal symptoms depends upon the type and severity. THIOTHIXENE: adverse_reactions: Rapid relief of acute symptoms may require the use of an injectable antiparkinson [0m
[31magent. More slowly emerging symptoms may be managed by reducing the dosage of thiothixene and/or administering an oral antiparkinson agent. Dystonia Class effect Symptoms of dystonia, prolonged [0m
[31mabnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to [0m
[31mtightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity[0m
[31mwith high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: openfda: spl_id         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: description: Each Thiothixene Capsules, USP contains [0m[1;31m1[0m[31m mg, [0m[1;31m2[0m[31m mg, [0m[1;31m5[0m[31m mg or [0m[1;31m10[0m[31m mg of thiothixene, USP and the following inactive ingredients: colloidal silicon dioxide, [0m
[31mcroscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch and sodium lauryl sulfate. Each empty hard gelatin capsule contains gelatin, iron [0m
[31moxide red, iron oxide yellow, purified water and titanium dioxide. In addition, the [0m[1;31m1[0m[31m mg hard gelatin capsule contains D&C yellow [0m[1;31m10[0m[31m, FD&C blue [0m[1;31m1[0m[31m and FD&C red [0m[1;31m40[0m[31m. The [0m[1;31m2[0m[31m mg hard gelatin capsule also [0m
[31mcontains D&C yellow [0m[1;31m10[0m[31m and ferrosoferric oxide. The [0m[1;31m5[0m[31m mg and [0m[1;31m10[0m[31m mg hard gelatin capsule also contains ferrosoferric oxide. THIOTHIXENE: description: The capsule is imprinted with black pharmaceutical [0m
[31mink which contains ferrosoferric oxide, potassium hydroxide, propylene glycol and shellac. THIOTHIXENE: description: structure         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: openfda: package_ndc         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: boxed_warning: WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs [0m
[31mare at an increased risk of death. Analyses of seventeen placebo-controlled trials [0m[1;31m([0m[31mmodal duration of [0m[1;31m10[0m[31m weeks[0m[1;31m)[0m[31m, largely in patients taking atypical antipsychotic drugs, revealed a risk of death in [0m
[31mdrug-treated patients of between [0m[1;31m1.6[0m[31m to [0m[1;31m1.7[0m[31m times the risk of death in placebo-treated patients. Over the course of a typical [0m[1;31m10[0m[31m-week controlled trial, the rate of death in drug-treated patients was [0m
[31mabout [0m[1;31m4.5[0m[31m%, compared to a rate of about [0m[1;31m2.6[0m[31m% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular [0m[1;31m([0m[31me.g., heart failure, sudden death[0m[1;31m)[0m
[31mor infectious [0m[1;31m([0m[31me.g., pneumonia[0m[1;31m)[0m[31m in nature. THIOTHIXENE: boxed_warning: Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may [0m
[31mincrease mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some [0m[1;31mcharacteristic[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m of the patients is[0m
[31mnot clear. Thiothixene is not approved for the treatment of patients with dementia-related psychosis [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: warnings: Neuroleptic Malignant Syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m has been reported in association [0m
[31mwith antipsychotic drugs, including thiothixene [0m[1;31m2[0m[31m . Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability [0m[1;31m([0m[31mirregular pulse or [0m
[31mblood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias[0m[1;31m)[0m[31m. The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify [0m
[31mcases where the clinical presentation includes both serious medical illness [0m[1;31m([0m[31me.g., pneumonia, systemic infection, etc.[0m[1;31m)[0m[31m and untreated or inadequately treated extrapyramidal signs and symptoms [0m[1;31m([0m[31mEPS[0m[1;31m)[0m[31m. [0m
[31mOther important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system [0m[1;31m([0m[31mCNS[0m[1;31m)[0m[31m pathology. THIOTHIXENE: [0m
[31mwarnings: The management of NMS should include [0m[1;31m1[0m[1;31m)[0m[31m immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, [0m[1;31m2[0m[1;31m)[0m[31m intensive symptomatic treatment and medical [0m
[31mmonitoring, and [0m[1;31m3[0m[1;31m)[0m[31m treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens [0m
[31mfor uncomplicated NMS. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be [0m
[31mcarefully monitored, since recurrences of NMS have been reported. Pregnancy Safe use of thiothixene during pregnancy has not been established. Therefore, this drug should be given to pregnant patients[0m
[31monly when, in the judgment of the physician, the expected benefits from the treatment exceed the possible risks to mother and fetus. THIOTHIXENE: warnings: Non-teratogenic Effects Neonates exposed to [0m
[31mantipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, [0m
[31mtremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases [0m
[31mneonates have required intensive care unit support and prolonged hospitalization. Thiothixene should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. [0m
[31mAnimal reproduction studies and clinical experience to date have not demonstrated any teratogenic effects. In the animal reproduction studies with thiothixene, there was some decrease in conception [0m
[31mrate and litter size, and an increase in resorption rate in rats and rabbits. Similar findings have been reported with other psychotropic agents. THIOTHIXENE: warnings: After repeated oral [0m
[31madministration of thiothixene to rats [0m[1;31m([0m[1;31m5[0m[31m to [0m[1;31m15[0m[31m mg/kg/day[0m[1;31m)[0m[31m, rabbits [0m[1;31m([0m[1;31m3[0m[31m to [0m[1;31m50[0m[31m mg/kg/day[0m[1;31m)[0m[31m, and monkeys [0m[1;31m([0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/day[0m[1;31m)[0m[31m before and during gestation, no teratogenic effects were seen. Usage in Children [0m
[31mThe use of thiothixene in children under [0m[1;31m12[0m[31m years of age is not recommended because safe conditions for its use have not been established. As is true with many CNS drugs, thiothixene may impair the [0m
[31mmental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery, especially during the first few days of therapy. Therefore, [0m
[31mthe patient should be cautioned accordingly. As in the case of other CNS-acting drugs, patients receiving thiothixene should be cautioned about the possible additive effects [0m[1;31m([0m[31mwhich may include [0m
[31mhypotension[0m[1;31m)[0m[31m with CNS depressants and with alcohol.         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: precautions: PRECAUTIONS An antiemetic effect was observed in animal studies with thiothixene; since this effect may also occur in man, it is possible that thiothixene may mask [0m
[31msigns of overdosage of toxic drugs and may obscure conditions such as intestinal obstruction and brain tumor. In consideration of the known capability of thiothixene and certain other psychotropic [0m
[31mdrugs to precipitate convulsions, extreme caution should be used in patients with a history of convulsive disorders or those in a state of alcohol withdrawal, since it may lower the convulsive [0m
[31mthreshold. Although thiothixene potentiates the actions of the barbiturates, the dosage of the anticonvulsant therapy should not be reduced when thiothixene is administered concurrently. Though [0m
[31mexhibiting rather weak anticholinergic properties, thiothixene should be used with caution in patients who might be exposed to extreme heat or who are receiving atropine or related drugs. THIOTHIXENE:[0m
[31mprecautions: Use with caution in patients with cardiovascular disease. Caution as well as careful adjustment of the dosages is indicated when thiothixene is used in conjunction with other CNS [0m
[31mdepressants. Also, careful observation should be made for pigmentary retinopathy and lenticular pigmentation [0m[1;31m([0m[31mfine lenticular pigmentation has been noted in a small number of patients treated with [0m
[31mthiothixene for prolonged periods[0m[1;31m)[0m[31m. Blood dyscrasias [0m[1;31m([0m[31magranulocytosis, pancytopenia, thrombocytopenic purpura[0m[1;31m)[0m[31m, and liver damage [0m[1;31m([0m[31mjaundice, biliary stasis[0m[1;31m)[0m[31m have been reported with related drugs. [0m
[31mAntipsychotic drugs, including thiothixene [0m[1;31m3[0m[31m , elevate prolactin levels; the elevation persists during chronic administration. THIOTHIXENE: precautions: Tissue culture experiments indicate that [0m
[31mapproximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously [0m
[31mdetected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown [0m
[31mfor most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical studies nor epidemiologic studies conducted to date,[0m
[31mhowever, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time. THIOTHIXENE:[0m
[31mprecautions: Leukopenia, Neutropenia and Agranulocytosis Class Effect In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia and agranulocytosis have been reported [0m
[31mtemporally related to antipsychotic agents. Possible risk factors for leukopenia/neutropenia include preexisting low white blood cell count [0m[1;31m([0m[31mWBC[0m[1;31m)[0m[31m and history of drug induced leukopenia/neutropenia. [0m
[31mPatients with a history of a clinically significant low WBC or drug induced leukopenia/neutropenia should have their complete blood count [0m[1;31m([0m[31mCBC[0m[1;31m)[0m[31m monitored frequently during the first few months of [0m
[31mtherapy and discontinuation of thiothixene should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors. Patients with clinically [0m
[31msignificant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. THIOTHIXENE: precautions: Patients with [0m
[31msevere neutropenia [0m[1;31m([0m[31mabsolute neutrophil count < [0m[1;31m1000[0m[31m/mm [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m should discontinue thiothixene and have their WBC followed until recovery. Information for Patients Given the likelihood that some patients [0m
[31mexposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The [0m
[31mdecision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided. Drug [0m
[31mInteractions Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. Patients receiving these drugs should be observed for [0m
[31msigns of reduced thiothixene effectiveness [0m[1;31m4[0m[31m,[0m[1;31m5[0m[31m . THIOTHIXENE: precautions: Due to a possible additive effect with hypotensive agents, patients receiving these drugs should be observed closely for [0m
[31msigns of excessive hypotension when thiothixene is added to their drug regimen [0m[1;31m6[0m[31m .         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: dosage_and_administration: DOSAGE AND ADMINISTRATION Dosage of thiothixene capsules should be individually adjusted depending on the chronicity and severity of the symptoms of [0m
[31mschizophrenia. In general, small doses should be used initially and gradually increased to the optimal effective level, based on patient response. Some patients have been successfully maintained on [0m
[31monce-a-day thiothixene capsules therapy. The use of thiothixene capsules in children under [0m[1;31m12[0m[31m years of age is not recommended because safe conditions for its use have not been established. In milder [0m
[31mconditions, an initial dose of [0m[1;31m2[0m[31m mg three times daily is recommended. If indicated, a subsequent increase to [0m[1;31m15[0m[31m mg/day total daily dose is often effective. In more severe conditions, an initial dose [0m
[31mof [0m[1;31m5[0m[31m mg twice daily is recommended. The usual optimal dose is [0m[1;31m20[0m[31m mg to [0m[1;31m30[0m[31m mg daily. If indicated, an increase to [0m[1;31m60[0m[31m mg/day total daily dose is often effective. THIOTHIXENE: dosage_and_administration: [0m
[31mExceeding a total daily dose of [0m[1;31m60[0m[31m mg rarely increases the beneficial response.         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: openfda: product_ndc         [0m
[31mSOURCE:THIOTHIXENE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Thiothixene has not been specifically reported to increase or decrease the risk of myocardial infarction. However, the label mentions cardiovascular effects such as tachycardia, hypotension, [0m
[32mlightheadedness, and syncope, and nonspecific EKG changes have been observed in some patients receiving thiothixene. These changes are usually reversible and frequently disappear on continued therapy.[0m
[32mThe clinical significance of these changes is not known. Additionally, the boxed warning indicates that elderly patients with dementia-related psychosis treated with antipsychotic drugs, including [0m
[32mthiothixene, are at an increased risk of death, with most of the deaths appearing to be either cardiovascular [0m[1;32m([0m[32me.g., heart failure, sudden death[0m[1;32m)[0m[32m or infectious [0m[1;32m([0m[32me.g., pneumonia[0m[1;32m)[0m[32m in nature. It is [0m
[32mimportant to note that thiothixene is not approved for the treatment of patients with dementia-related psychosis.[0m

[32mSOURCE: THIOTHIXENE label[0m
[32mEXTRACT_START_END: Cardiovascular Effects Tachycardia, hypotension, lightheadedness[0m[32m...[0m[32m The clinical significance of these changes is not known.[0m
*[1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Thiothixene has not been specifically reported to [0m
[34mincrease or decrease the risk of myocardial infarction. However, the label mentions cardiovascular effects such as tachycardia, hypotension, lightheadedness, and syncope, and nonspecific EKG changes [0m
[34mhave been observed in some patients receiving thiothixene. These changes are usually reversible and frequently disappear on continued therapy. The clinical significance of these changes is not known. [0m
[34mAdditionally, the boxed warning indicates that elderly patients with dementia-related psychosis treated with antipsychotic drugs, including thiothixene, are at an increased risk of death, with most of[0m
[34mthe deaths appearing to be either cardiovascular [0m[1;34m([0m[34me.g., heart failure, sudden death[0m[1;34m)[0m[34m or infectious [0m[1;34m([0m[34me.g., pneumonia[0m[1;34m)[0m[34m in nature. It is important to note that thiothixene is not approved for the [0m
[34mtreatment of patients with dementia-related psychosis.[0m

[34mSOURCE: THIOTHIXENE label[0m
[34mEXTRACT_START_END: Cardiovascular Effects Tachycardia, hypotension, lightheadedness[0m[34m...[0m[34m The clinical significance of these changes is not known.[0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThe FDAHandler has indicated that thiothixene has not been [0m
[32mspecifically reported to increase or decrease the risk of myocardial infarction. The label does mention cardiovascular effects such as tachycardia, hypotension, lightheadedness, and syncope, and [0m
[32mnonspecific EKG changes have been observed in some patients receiving thiothixene. These changes are usually reversible and frequently disappear on continued therapy, but the clinical significance of [0m
[32mthese changes is not known. Additionally, the boxed warning indicates that elderly patients with dementia-related psychosis treated with antipsychotic drugs, including thiothixene, are at an increased[0m
[32mrisk of death, with most of the deaths appearing to be either cardiovascular [0m[1;32m([0m[32me.g., heart failure, sudden death[0m[1;32m)[0m[32m or infectious [0m[1;32m([0m[32me.g., pneumonia[0m[1;32m)[0m[32m in nature. However, it is important to note that [0m
[32mthiothixene is not approved for the treatment of patients with dementia-related psychosis.[0m

[32mGiven this information, we cannot definitively say whether thiothixene increases or decreases the risk of myocardial infarction, as the FDA label does not specify this information. The cardiovascular [0m
[32meffects mentioned could potentially be related to myocardial infarction risk, but there is no clear evidence or specific mention of myocardial infarction in the context of thiothixene use. Therefore, [0m
[32mthe answer to the question is DO-NOT-KNOW.[0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does THIOTHIXENE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if thiothixene increases or decreases the risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that thiothixene has not been specifically reported to increase or decrease the risk of myocardial infarction. However, cardiovascular effects such as tachycardia, [0m
[32mhypotension, lightheadedness, and syncope have been observed, and nonspecific EKG changes have been noted in some patients. The clinical significance of these changes is not known. Additionally, there[0m
[32mis an increased risk of death from cardiovascular causes in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including thiothixene, although it is not approved for [0m
[32mthis use."[0m[32m,[0m
[32m      [0m[32m"Based on this information from the FDA label, we cannot definitively determine if thiothixene increases or decreases the risk of myocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does THIOTHIXENE increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if thiothixene increases or decreases the risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that thiothixene has not been specifically reported to increase or decrease the risk of myocardial infarction. However, cardiovascular effects such as tachycardia, [0m
[34mhypotension, lightheadedness, and syncope have been observed, and nonspecific EKG changes have been noted in some patients. The clinical significance of these changes is not known. Additionally, there[0m
[34mis an increased risk of death from cardiovascular causes in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including thiothixene, although it is not approved for [0m
[34mthis use."[0m[34m,[0m
[34m      [0m[34m"Based on this information from the FDA label, we cannot definitively determine if thiothixene increases or decreases the risk of myocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does THIOTHIXENE increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if thiothixene increases or decreases the risk of myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded that thiothixene has not been specifically reported to increase or decrease the risk of myocardial infarction. However, cardiovascular effects such as tachycardia, hypotension,[0m
[31mlightheadedness, and syncope have been observed, and nonspecific EKG changes have been noted in some patients. The clinical significance of these changes is not known. Additionally, there is an [0m
[31mincreased risk of death from cardiovascular causes in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including thiothixene, although it is not approved for this [0m
[31muse.[0m
[1;31m3[0m[31m. Based on this information from the FDA label, we cannot definitively determine if thiothixene increases or decreases the risk of myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDAHandler has indicated that thiothixene has not been specifically reported to increase or decrease the risk of myocardial infarction. While the label mentions cardiovascular effects such as [0m
[32mtachycardia, hypotension, lightheadedness, and syncope, and nonspecific EKG changes in some patients, the clinical significance of these changes is not known. Additionally, there is an increased risk [0m
[32mof death from cardiovascular causes in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including thiothixene, although it is not approved for this use. Given the [0m
[32mlack of specific information regarding myocardial infarction, we cannot definitively say whether thiothixene increases or decreases the risk of this condition.[0m
